FDA Panel Recommends EUA for Novavax COVID-19 Vaccine
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]
FDA Flags Risk of Myocarditis in Novavax COVID Vaccine
Novavax, one of the worst performers on Wall Street, and that is after an FDA warning on its COVID vaccine. Year to date, down 68 percent. Of course, that coming as a result of the FDA out with their analysis from Novavax’s data that they submitted for the emergency use filing for the meeting coming […]
Novavax’s Protein COVID-19 Vaccine Now Available in Europe
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
U.S. Taxpayers Paid Billions of Dollars for COVID-19 Vaccine Development
According to the U.S. Centers for Disease Control and Prevention (CDC), the federal government of the United States is providing COVID-19 vaccines free of charge to everyone five years and older living in the United States, regardless of their immigration or health insurance status.1 Although the CDC states that COVID vaccines are provided to the […]
Moderna, Novavax Developing Combined Single-Dose COVID-19 and Influenza Vaccine
American pharmaceutical and biotechnology company Moderna, Inc., which partnered with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) to develop an mRNA COVID-19 vaccine being distributed in the United States under an Emergency Use Authorization (EUA) announced that it is developing a combined single-dose booster vaccine for COVID-19 and seasonal influenza.1 In a […]
Pharma’s Public Pledge On COVID-19 Vaccines
On Sept. 8, 2020, nine pharmaceutical companies working on COVID-19 vaccines signed a pledge saying they would not submit their experimental vaccines to the U.S. Food and Drug Administration (FDA) unless they were shown to be both safe and efficacious in the Phase 3 human clinical trials.1 2 3 4 5 The pledge, signed by […]
